The Weekly Roundup: April 20-24

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

40 Years of the ABCDs: Darrell Rigel, MD, MS, Reflects on the Evolution of Global Melanoma Detection

Four decades ago, a deceptively simple mnemonic transformed how clinicians, and eventually the public, recognized melanoma.

Phase 2b 52-Week Extension Results Demonstrate Sustained Hair Regrowth with Rezpegaldesleukin

REZPEG shows growing hair regrowth at 52 weeks in severe alopecia areata, with favorable safety, hinting at a new biologic alternative to JAKs.

Galderma Unveils New Interim Trial Data on Menopause and Weight Loss-Driven Skin Changes

Interim investigator-initiated trials reveal how Restylane Skinboosters and Sculptra could improve menopausal skin and address GLP-1 weight-loss volume changes.

Could Dupilumab Treat Depression? Mount Sinai Study Targets Immune Link

The study represents a repurposing strategy, using dupilumab as a tool compound to probe whether immune-targeted therapy can address a biologically defined subgroup of MDD.

From Burden to Breakthrough: Redefining the Standard of Care in Hidradenitis Suppurativa

Building trust through empathetic communication, education, and support resources is essential to improving outcomes for patients with HS.

Hormonal Transitions Drive Unique Psychodermatologic Burden in Women Across the Lifespan

A meta-analysis cited in the review found depression prevalence among melasma patients at 43.4% — approximately 12 times the estimated global rate — highlighting the psychiatric weight.

Upadacitinib Phase 3 Trials Identify Psychological and Functional Benefits of Ambitious Treatment Targets in AD

Post hoc trial data presented at AAD 2026 show near-clear atopic dermatitis and minimal itch drive bigger gains in quality of life, sleep, mental health, and satisfaction.

AI-Driven DERMACLEAR Insights Into the Real-World Burden of Chronic Inflammatory Skin Diseases

AI-analyzed EHRs show a surging burden of hidradenitis suppurativa, chronic urticaria, psoriasis, and eczema, with major comorbidities, costly care, and low biologic use.

Pediatric AD Referrals Reveal Treatment Gaps in Primary Care

Most AD referrals were low urgency, contributing to prolonged wait times exceeding 30 weeks on average.

Journal Digest: April 22, 2026

This review of the latest dermatological studies includes insights on minoxidil in onychodystrophy, telehealth outcomes in HS patients, pediatric AD referrals, and more.

From Symptoms to Signaling Pathways in Seborrheic Dermatitis

Patients frequently experience persistent symptoms, visible lesions, and recurrent flares that affect daily functioning and self-image.

Durability of Patient-Reported Outcomes in AD: 140-Week Results From Measure Up 1 and 2

New 140-week data show that upadacitinib keeps itch, sleep, and quality-of-life gains steady in patients with moderate to severe atopic dermatitis (AD).

Itch First: Reframing Treatment Goals in Atopic Dermatitis

Clinicians agreed that itch — not lesion count or BSA alone — is the most clinically meaningful driver of treatment escalation in patients with atopic dermatitis.

FDA Approves Dupilumab for Chronic Spontaneous Urticaria in Children Aged 2 to 11

The biologic is the first of its kind approved for young children with antihistamine-refractory CSU, expanding an existing indication that previously covered adults and adolescents.

Are We Experiencing a Mass Extinction of the Skin Microbiome?

Although microbes inhabit many body sites, the skin is one of the most densely populated areas after the gastrointestinal tract.

ICYMI: Medicus Pharma Seeks FDA Orphan Drug Designation for SkinJect in Gorlin Syndrome

Medicus seeks FDA orphan drug status for SkinJect, a dissolvable microneedle doxorubicin patch targeting Gorlin-related basal cell carcinomas, aiming to reduce the need for repeated surgery.

New Study Reveals a Decade of Insights on Dermatologic Complications in Renal Transplant Recipients

Renal transplant patients face frequent warts, fungal infections, and steroid acne, according to new 10-year data.

More Than Medicine: Key Takeaways on Career Growth From Winter Clinical Miami Experts

At the 2026 Winter Clinical Miami meeting, dermatology leaders emphasized that thriving careers require skills beyond clinical expertise.

Multispecific Biologics Aim to Redefine Treatment Targets in Atopic Dermatitis

Early clinical trials indicate that dual- and triple-target antibodies may provide faster onset and more consistent itch relief in moderate to severe AD.

FDA Issues Complete Response Letter for AbbVie’s Rapid-Onset Neurotoxin, TrenibotulinumtoxinE

Potential FDA approval of TrenibotE was delayed due to manufacturing-related issues, with no concerns regarding safety, efficacy, or clinical trial data.

The Aesthetic Edge: April 2026

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of April.

AAD 2026 Insights: Expanding Targets, Faster Responses, and Durable Control in Atopic Dermatitis Management

Gain exclusive insights from AAD on rapid-onset topicals, durable biologic control, and a growing emphasis on stringent, patient-centered targets shaping atopic dermatitis care.